New Stock News | Maiwei Biotech (688062.SH) Hong Kong IPO Prospectus Invalid

The Hong Kong stock prospectus submitted by Maverick (Shanghai) Biotechnology Co., Ltd. (Maverick Biotech) (688062.SH) on August 29, 2025 has expired after six months and is now invalid. According to the prospectus, Maverick Biotech is a pharmaceutical company focused on the independent development of drugs for tumors and age-related diseases in the commercialization stage. Over the years, the company has established a competitive and multi-tiered pipeline product portfolio, including more than 10 drug assets covering different varieties, focusing on tumors and age-related diseases such as immunology, ophthalmology, orthopedics, and other fields.